Habib Ur Rehman
Wed, June 17, 2026 astatine 10:17 AM CDT 2 min read
The update adds an earlier-stage plus down Olema's main palazestrant program, wherever the much contiguous valuation catalyst remains OPERA-01. In its May 12 first-quarter update, Olema said topline information from the Phase 3 OPERA-01 proceedings of palazestrant arsenic a monotherapy successful second- and third-line ER+/HER2- metastatic bosom crab are expected successful autumn 2026. The institution besides said its Phase 3 OPERA-02 proceedings of palazestrant successful operation with ribociclib successful frontline metastatic bosom crab continued to enroll patients. Olema ended the archetypal 4th with $505.3 cardinal successful cash, currency equivalents, and marketable securities.
Photo by National Cancer Institute connected Unsplash
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), operating arsenic Olema Oncology, is simply a clinical-stage biopharmaceutical institution processing targeted therapies for bosom crab and different cancers.
While we admit the imaginable of OLMA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey connected Google News.

1 hour ago
3




English (CA) ·
English (US) ·
Spanish (MX) ·